Results 91 to 100 of about 44,594 (195)

Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study

Malaria Journal, 2018
Background Plasmodium vivax malaria is characterized by relapses arising from the hypnozoite stages in the liver. The only currently registered drug for radical treatment to prevent relapse is primaquine.
Kanokpich Puaprasert, Cindy Chu, Naowarat Saralamba, Nicholas P. J. Day, Francois Nosten, Nicholas J. White, Arjen M. Dondorp, Mallika Imwong   +7 more
doaj   +1 more source

The CYP2D6 VCF Translator [PDF]

The Pharmacogenomics Journal, 2016
W, Qiao, J, Wang, B S, Pullman, R, Chen, Y, Yang, S A, Scott   +5 more
openaire   +2 more sources

Variantes alélicas de CYP2D6: *4, *6 y *10 en una muestra de residentes del estado Aragua, Venezuela

Revista Peruana de Medicina Experimental y Salud Pública
El objetivo del estudio fue determinar la frecuencia de las variantes del gen CYP2D6: *4, *6 y *10 y predecir el fenotipo metabolizador en una muestra de 145 individuos no consanguíneos, aparentemente sanos, residentes del estado Aragua, Venezuela.
Carlos Flores-Angulo, Cecilia Villegas, Yuselin Mora, José Antonio Martínez, Teresa Oropeza, Nancy Moreno   +5 more
doaj   +2 more sources

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity

Human Genomics
Background Individual assessment of CYP enzyme activities can be challenging. Recently, the potato alkaloid solanidine was suggested as a biomarker for CYP2D6 activity.
Johanna I. Kiiski, Mikko Neuvonen, Mika Kurkela, Päivi Hirvensalo, Kreetta Hämäläinen, E. Katriina Tarkiainen, Johanna Sistonen, Mari Korhonen, Sofia Khan, Arto Orpana, Anne M. Filppula, Marko Lehtonen, Mikko Niemi   +12 more
doaj   +1 more source

Duloksetins betydning for serumkonsentrasjonen av psykofarmaka som omsettes via CYP2D6 [PDF]

, 2009
Bakgrunn: Duloksetin er et relativt nytt antidepressivum som hemmer reopptak av serotonin og noradrenalin intersynaptisk. Det metaboliseres via Cytokrom P450 2D6 (CYP2D6) og CYP1A2, men antas også å være en svak/moderat hemmer av CYP2D6.
Enoksen, Torill Bakko
core  

Polymorphic drug metabolising enzymes:Assessment of activities by phenotyping and genotyping in clinical pharmacology [PDF]

, 2001
Drug effects (pharmacodynamics) are determined by drug concentration at target site and the affinity of the drug for a target. Pharmacogenetics describes inherited differences in drug metabolising enzyme activities and differences in drug transporters ...
Tamminga, Willem Jan
core   +2 more sources

FROM THE EDITOR

Фармакокинетика и Фармакодинамика, 2014
В настоящем номере представлен ряд актуальных обзоров, посвящённых изучению новых лекарственных средств и межлекарственному взаимодействию. Прежде всего, продолжается серия обзоров, связанных с исследованием функционирования и полиморфизма известных ...

doaj  

Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen. [PDF]

, 2010
Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early and advanced stage breast cancer in women and men. It is a pro-drug having weak affinity with the estrogen receptor and needs to be converted to its main metabolite, endoxifen ...
Berthod, G., Bodmer, A., Buclin, T., Csajka, C., Dahmane, E., Decosterd, L., Eap, C., Galmiche, M., Leyvraz, S., Perey, L., Zaman, K.   +10 more
core  

Review of existing methodologies to assess the activity of CYP2D6 using exogenous and endogenous markers

Фармакокинетика и Фармакодинамика, 2014
Peculiarities of functioning and polymorphism of cytochrome P450 isoenzyme CYP2D6. Existing methods for determining its activity using endogenous markers.
A. D. Abdrashitov, G. N. Gildeeva, G. V. Ramenskaya, V. V. Smirnov   +3 more
doaj  

DEVELOPMENT AND VALIDATION OF SIMULTANEOUS ASSAY OF SUBSTRATES-MARKERS OF MAIN CYTOCHROME P450 ISOFORMS AND THEIR METABOLITES USING HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2019
Simultaneous quantification method of assaying main CYP isoforms substrates-markers and their metabolites in urine using HPLC-MS/MS was developed to determine activity of following isoforms: caffeine/paraxanthine for CYP1A2, losartane/E-3174 for CYP2C9 ...
E. A. Egorenkov, V. V. Smirnov
doaj